| A Study to Test Inavolisib Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
Nature et Objective
A Phase II, Randomized, Multicenter, Open-Label Study. This study will evaluate the efficacy and safety of the combination of Inavolisib plus Enzalutamide compared with physician’s choice of alternative androgen receptor pathway inhibitor (ARPi) or Docetaxel in biomarker-selected participants with metastatic castrate-resistant prostate cancer (mCRPC) who have received one prior second-generation ARPi.
Stade de la Maladie: Métastatique
Organe: Prostate
Maladie: mCRPC